Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 10 Mar 2023
New findings from researchers at Wake Forest University School of Medicine show that the rate of type 1 and type 2 diabetes is increasing...
Read Full NewsMind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Benjamin Tolchin, MD, MS, FAAN. [LISTEN TIME: 23 minutes]
Alixorexton, an oral investigational selective orexin 2 receptor agonist, is currently in development for the treatment of narcolepsy type 1 and type 2, and idiopathic hypersomnia.
1.
An inoperable locally advanced NSCLC trial dubbed "Practice Changing".
2.
Study finds 1 in 12 patients labeled as having 'benign' results actually had high-risk prostate cancer
3.
Biomarker panel offers hope for early pancreatic cancer detection
4.
For patients with clear cell renal cell carcinoma, a new PET agent allows for same-day imaging.
5.
In leukemia, allogeneic HCT is beneficial following primary induction failure.
1.
Unveiling the Secrets of Early Cancer: Emerging Strategies to Decipher Its Biology
2.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
3.
The benefits and risks of taking fludrocortisone for adrenal insufficiency
4.
Revolutionizing Thyroid Cancer: Advances in Molecular Genetics and Personalized Treatment Approaches
5.
Revolutionizing Cancer Care: The Transformative Role of AI and Data Science in Oncology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
3.
Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment
4.
Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge